#1 Clinical Trials Search in Europe

Palivizumab

Palivizumab is a monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and young children. This article summarizes key findings from clinical trials evaluating the safety and effectiveness of palivizumab for RSV prevention. The trials examined palivizumab use in premature infants, children with chronic lung disease or congenital heart disease, and as a potential treatment for active RSV infections.

Table of Contents

What is Palivizumab?

Palivizumab, also known by its brand name Synagis[1], is a medication used to prevent serious lower respiratory tract infections caused by the Respiratory Syncytial Virus (RSV). RSV is a common virus that can cause severe breathing problems, especially in infants and young children with certain risk factors.

Palivizumab is a type of medicine called a monoclonal antibody. This means it’s a laboratory-made protein that mimics the immune system’s ability to fight off harmful pathogens like viruses[2]. Specifically, Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets a specific part of the RSV virus, helping to prevent it from causing infection[1].

How Does Palivizumab Work?

Palivizumab works by binding to a specific protein on the surface of the RSV virus called the F protein. This F protein is crucial for the virus to enter and infect human cells. By attaching to this protein, Palivizumab prevents the virus from infecting cells in the respiratory tract, thus reducing the risk of severe RSV infection[1].

Unlike traditional vaccines that stimulate the body to produce its own antibodies, Palivizumab provides ready-made antibodies. This approach is particularly beneficial for infants and young children who may not have a fully developed immune system or those with conditions that compromise their ability to fight infections effectively[3].

What Conditions Does Palivizumab Treat?

Palivizumab is primarily used to prevent serious lower respiratory tract disease caused by RSV in children who are at high risk. This includes:

  • Premature infants: Babies born at or before 35 weeks gestational age and who are 6 months old or younger at the start of the RSV season[1].
  • Children with chronic lung disease (CLD) of prematurity: Those who have required medical treatment within the previous 6 months and are 24 months old or younger[1].
  • Children with hemodynamically significant congenital heart disease (CHD): Those who are 24 months old or younger[1].
  • Children with immunocompromised conditions: Some studies have explored the use of Palivizumab in children with weakened immune systems who are 24 months old or younger[2].

How is Palivizumab Administered?

Palivizumab is typically administered as an intramuscular injection (a shot into the muscle). The usual dosage is 15 mg per kilogram of body weight[1]. It’s usually given once a month during the RSV season, which typically runs from fall through spring in most areas.

The number of doses a child receives depends on when they start treatment and their risk factors. Generally, children receive between 3 to 5 monthly doses during the RSV season[1]. It’s important to note that Palivizumab is used for prevention, not for treating active RSV infections.

Effectiveness of Palivizumab

Studies have shown that Palivizumab can significantly reduce the risk of RSV-related hospitalizations in high-risk infants and children. In clinical trials, it has been found to:

  • Reduce RSV hospitalizations by up to 55% in premature infants and children with chronic lung disease[1].
  • Decrease the number of days of RSV hospitalization and the days with increased oxygen requirements[1].
  • Reduce the incidence of intensive care unit (ICU) admissions due to RSV[1].

However, it’s important to note that while Palivizumab is effective at reducing the risk of severe RSV disease, it does not prevent all RSV infections[3].

Safety and Side Effects

Palivizumab is generally considered safe and well-tolerated. However, like all medications, it can cause side effects. The most common side effects reported include:

  • Fever
  • Rash
  • Injection site reactions (such as pain or redness)

Serious allergic reactions, including anaphylaxis, have been reported very rarely[5]. As with any medication, it’s important to discuss potential risks and benefits with your healthcare provider.

Ongoing Research

Research on Palivizumab is ongoing, with several studies exploring its use in different populations and settings. Some areas of current research include:

  • Extended use: Studies are looking at the effectiveness of Palivizumab beyond the typical 5-dose regimen[4].
  • Use in healthy adults: Some research is exploring the potential of Palivizumab to prevent RSV infection in healthy adults, which could provide insights into its mechanism of action and potential broader applications[5].
  • Comparison with new treatments: Studies are comparing Palivizumab with newer monoclonal antibodies developed for RSV prevention, such as MEDI8897[4].

These ongoing studies aim to further our understanding of Palivizumab and potentially expand its use in preventing RSV infections across different populations.

Aspect Details
Drug Name Palivizumab (Brand name: Synagis)
Type Monoclonal antibody
Primary Use Prevention of severe RSV infections in high-risk infants and young children
Administration Intramuscular injection, typically 15 mg/kg monthly during RSV season
Target Population Premature infants, children with chronic lung disease or congenital heart disease
Key Outcomes Reduction in RSV hospitalizations, decreased severity of RSV infections
Safety Profile Generally well-tolerated, common side effects include injection site reactions and fever
Efficacy Shown to be effective in reducing RSV-related hospitalizations in high-risk groups
Ongoing Research Evaluation in new populations, potential use as treatment for active RSV infections

FAQ

  • What is palivizumab used for? Palivizumab is used to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and young children, such as those born prematurely or with chronic lung disease or congenital heart disease.
  • How is palivizumab administered? Palivizumab is typically administered as an intramuscular injection, given monthly during the RSV season. The usual dose is 15 mg/kg of body weight.
  • What are the main outcomes measured in palivizumab clinical trials? The main outcomes measured include RSV hospitalization rates, length of hospital stay, need for intensive care or mechanical ventilation, and safety measures such as adverse events and development of anti-drug antibodies.
  • Is palivizumab effective in preventing RSV infections? Clinical trials have shown that palivizumab is effective in reducing RSV hospitalizations in high-risk infants and young children when used as preventive therapy during RSV season.
  • What are the potential side effects of palivizumab? Common side effects may include injection site reactions, fever, and upper respiratory tract infections. Serious allergic reactions are rare but possible. The safety profile is generally favorable in clinical trials.

Ongoing Clinical Trials on Palivizumab

  • Study on the Safety and Effectiveness of Clesrovimab and Palivizumab for Preventing Severe RSV in Infants and Children at High Risk

    Not recruiting

    3 1 1
    Investigated drugs:
    Czechia Finland France Germany Greece Hungary +3

  • Study on Preventing Respiratory Issues from RSV Bronchiolitis in Preterm Babies Using Palivizumab

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Respiratory Syncytial Virus (RSV): A common respiratory virus that usually causes mild, cold-like symptoms. In infants and older adults, RSV can cause severe infections like bronchiolitis and pneumonia.
  • Palivizumab: A monoclonal antibody medication used to prevent severe RSV infections in high-risk infants and young children. It is given as a monthly injection during RSV season.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In the case of palivizumab, it binds to RSV to help prevent infection.
  • Chronic Lung Disease (CLD): A general term for long-term respiratory problems in premature babies. It is also known as bronchopulmonary dysplasia (BPD).
  • Congenital Heart Disease (CHD): Heart defects that are present at birth. These structural problems in the heart can increase the risk of severe RSV infection.
  • Intramuscular injection: A technique used to deliver a medication deep into the muscles. This allows the medication to be absorbed into the bloodstream quickly.
  • RSV season: The time of year when RSV infections are most common, typically fall through spring in temperate climates.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Anti-drug antibody (ADA): Antibodies produced by the immune system against a therapeutic drug, which can potentially reduce the drug's effectiveness.
  • Immunocompromised: Having a weakened immune system, which can be due to certain medical conditions or treatments, making a person more susceptible to infections.

References

  1. https://clinicaltrials.gov/study/NCT02968173
  2. https://clinicaltrials.gov/study/NCT01466062
  3. https://clinicaltrials.gov/study/NCT02442427
  4. https://clinicaltrials.gov/study/NCT03959488
  5. https://clinicaltrials.gov/study/NCT04540627